Global EditionASIA 中文雙語(yǔ)Fran?ais
    China
    Home / China / Latest

    Pandemic's long-term effects fuel debate

    By ZHANG ZHIHAO | China Daily | Updated: 2020-07-31 07:02
    Share
    Share - WeChat
    A medical staff member is seen next to a patient suffering from the coronavirus disease (COVID-19) in the intensive care unit at the Circolo hospital in Varese, Italy, April 9, 2020. [Photo/Agencies]

    Double-edged sword

    Yi Fan, a doctor from Wuhan, contracted the virus, which left his skin darkened, while treating patients at the start of the outbreak. He has been known fondly by netizens as the "dark-faced angel", although recent photos show that his skin color has much improved.

    For his peers, Yi's case serves as a reminder that COVID-19 requires scrupulous care.

    During a media briefing in May, Duan Jun, a senior intensive care physician at the China-Japan Friendship Hospital in Beijing, said the skin darkening was due to a combination of the antifungal drug Polymyxin B and liver damage, which caused iron to build up in the blood.

    Mao Yonghui, a senior nephrologist at Beijing Hospital who treated severe cases of COVID-19 in Wuhan, said medical workers must take the adverse effects of medication into account, as many of the powerful drugs being used can damage the liver, kidneys and gastrointestinal system.

    "Most of the drugs' side effects can be mitigated through careful use and meticulous monitoring," she said. "The long-term consequences of the virus are puzzling enough, so the last thing we want is for the treatment to have any long-lasting effects."

    According to the World Health Organization, no effective drugs are currently available to combat COVID-19. However, some potential candidates have recently received a considerable amount of hype and endorsement from the media and politicians. These drugs include the experimental antiviral remdesivir and dexamethasone, a steroid.

    The journal Science reported that the US government recently stockpiled enough supplies of remdesivir for three months. The UK and Japan have made dexamethasone part of the care for patients in critical condition after a preliminary study found that the steroid could reduce mortality by about one-third for those on ventilators, the report said.

    However, Mao said an apparent lack of reporting on the adverse effects of the drugs, which can pose long-term health risks if not taken properly, remains a concern.

    "The more encouraging a candidate drug is, the more careful doctors and public health officials should be when giving it to the public," she said. "But we know such rationality is in short supply, especially during a pandemic."

    The adverse effects of remdesivir in treating COVID-19 remain unclear, as the drug is still being developed. However, evidence of risk to the liver and kidneys has been reported and is under intense scientific scrutiny, according to studies published in The Lancet and New England Journal of Medicine.

    A Beijing orthopedist, speaking on condition of anonymity, said he was deeply concerned when the UK and Japan rushed to approve dexamethasone as a standard treatment for critically ill COVID-19 patients, based on early evidence.

    "Dexamethasone, prednisone and methylprednisolone were among the corticosteroids (steroid hormones produced in the adrenal cortex or made synthetically) widely used by doctors during the SARS epidemic. High-dosage patients experienced bone tissue death, diabetes, psychosis and other chronic conditions," he said.

    In January, a clinical guideline released by the WHO advised against the routine administering of corticosteroids to treat viral pneumonia and ARDS-two conditions caused by COVID-19. The advice was based on studies of the drugs' long-term side effects on SARS patients. However, the guideline also stressed that studies had notable design flaws and should be treated with a degree of skepticism.

    The Beijing orthopedist said: "I believe that when pulling critically ill patients away from death's door, all options should be on the table, including dexamethasone, which is a cheap and accessible drug. The key is administering it with extreme care and caution."

    In China, the national guideline on COVID-19 care states that patients can receive three to five days of treatment with corticosteroids based on their symptoms, but the daily dosage cannot exceed 1 milligram to 2 milligrams per kilogram of body weight. Meanwhile, the immunosuppressive effect and delayed viral clearance-the time in which a virus can no longer be detected in blood tests-caused by the steroids must be accounted for.

    In an open letter published in The Lancet in late February, five Chinese doctors said the benefits and harm caused by using corticosteroids must be considered carefully. Dosage should be low-to-moderate, and the duration must be less than seven days.

    |<< Previous 1 2 3 4 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲av无码国产精品夜色午夜| 久久久久久人妻无码| 国产AV无码专区亚洲AVJULIA| 在线天堂资源www在线中文| 亚洲精品国产日韩无码AV永久免费网 | 国模无码人体一区二区| 亚洲人成无码网WWW| 日韩人妻无码一区二区三区99| 一本精品中文字幕在线| 久久精品天天中文字幕人妻| 日韩精品无码免费视频| 久久精品国产亚洲AV无码麻豆 | 免费看成人AA片无码视频吃奶| 亚洲欧美日韩中文在线制服| 国产亚洲情侣一区二区无码AV | 无码人妻一区二区三区精品视频| 亚洲爆乳精品无码一区二区三区| 亚洲国产中文v高清在线观看| 无码AV中文字幕久久专区| 亚洲国产精品无码久久久久久曰| 国产做无码视频在线观看浪潮| 无套内射在线无码播放| 最新无码A∨在线观看| 最近2019中文字幕一页二页| 五月丁香啪啪中文字幕| 中文字幕亚洲综合久久| 中文字幕一区二区人妻性色| 亚洲精品无码AV中文字幕电影网站| 亚洲综合无码一区二区| 国产精品亚洲专区无码WEB| (愛妃視頻)国产无码中文字幕| 国产精品无码av在线播放| 日韩av无码久久精品免费| 久久99精品久久久久久hb无码| 久久亚洲AV成人无码国产| 无码av免费网站| 国产a v无码专区亚洲av| 免费无遮挡无码视频在线观看| 中文国产成人精品久久亚洲精品AⅤ无码精品 | 亚洲成A∨人片天堂网无码| 久久精品99无色码中文字幕|